New shot aims to save sight in advanced macular degeneration

NCT ID NCT06990269

Recruiting now Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss of a key layer in the retina. Participants must have a certain size of retinal damage and be willing to get required vaccinations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ADARx Clinical Site
RECRUITING

Gilbert, Arizona, 85297, United States
ADARx Clinical Site
RECRUITING

Phoenix, Arizona, 85020, United States
ADARx Clinical Site
RECRUITING

Bakersfield, California, 93309, United States
ADARx Clinical Site
RECRUITING

Beverly Hills, California, 90211, United States
ADARx Clinical Site
RECRUITING

Huntington Beach, California, 93647, United States
ADARx Clinical Site
RECRUITING

Poway, California, 92064, United States
ADARx Clinical Site
RECRUITING

Orlando, Florida, 32806, United States
ADARx Clinical Site
RECRUITING

Wildwood, Florida, 34785, United States
ADARx Clinical Site
RECRUITING

Hagerstown, Maryland, 21740, United States
ADARx Clinical Site
RECRUITING

Reno, Nevada, 89502, United States
ADARx Clinical Site
WITHDRAWN

Erie, Pennsylvania, 16505, United States
ADARx Clinical Site
RECRUITING

Austin, Texas, 78705, United States
ADARx Clinical Site
RECRUITING

Bellaire, Texas, 77401, United States
ADARx Clinical Site
RECRUITING

Dallas, Texas, 75231, United States
ADARx Clinical Site
RECRUITING

McAllen, Texas, 78503, United States
ADARx Clinical Site
RECRUITING

Round Rock, Texas, 78681, United States
ADARx Clinical Site
RECRUITING

San Antonio, Texas, 78340, United States
ADARx Clinical Site
RECRUITING

The Woodlands, Texas, 77384, United States
ADARx Clinical Site
RECRUITING

St. George, Utah, 84790, United States
ADARx Clinical Site
RECRUITING

Albury, New South Wales, 2640, Australia
ADARx Clinical Site
RECRUITING

Hurstville, New South Wales, 2220, Australia
ADARx Clinical Site
RECRUITING

Parramatta, New South Wales, 2150, Australia
ADARx Clinical Site
RECRUITING

East Melbourne, Victoria, 3002, Australia
ADARx Clinical Site
RECRUITING

Rowville, Victoria, 3178, Australia
ADARx Clinical Site
RECRUITING

Vancouver, British Columbia, Canada
ADARx Clinical Site
RECRUITING

Ottawa, Ontario, K2B 7E9, Canada
ADARx Clinical Site
RECRUITING

Toronto, Ontario, M8X 2X3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.